






Antioxidant Supplementation in Cancer: 
Potential Interactions with Conventional Chemotherapy 





The use of supra-dietary doses of chemical antioxidants has attracted increasing interest as a possible primary 
and secondary cancer prevention strategy. It is possible that some cancer patients have an inherently impaired 
capacity to contend with oxidative stress because of genetic or environmental factors. Specifically, higher levels 
of intracellular antioxidants may protect against chromosomal injury induced by UV radiation and xenobiotic 
induced oxidative stress. Vitamin A and carotenoids, vitamin C, vitamin E, selenium, and glutathione may alone 
or in combination afford protection. Chemotherapy and radiation therapy result in depletion of tissue 
antioxidant stores. Antioxidant supplementation may be an important part of recovery from conventional 
therapy and perhaps have impact on secondary prevention. 
 
However, currently the greatest controversy surrounds the concomitant administration of supra-dietary doses of 
antioxidant agents during chemotherapy and/or radiation therapy. The remainder of this section intends to 
clarify the major issues surrounding this controversy by reviewing the current state of understanding about 
potential and established interaction between antioxidants and conventional oncological therapies. Toward this 
end it is useful to consider four focus questions: 
 
1. Does the co-administration of antioxidants decrease the effectiveness of chemotherapy and radiation 
therapy? 
2. Does the co-administration of antioxidants increase the effectiveness of chemotherapy and radiation 
therapy? 
3. Does the co-administration of antioxidants mitigate some of the side effects of chemotherapy and 
radiation therapy and improve quality of life? 
4. Does the co-administration of antioxidants favorably or unfavorably affect long-term survival rates?  
 
Historical position and rationale of medical and radiation oncologists. Chemotherapy-induced formation of free 
radicals is well demonstrated most notably with alkylating agents, anthracyclines, epipdophyllotoxins (eg. 
etoposide and teniposide), and antitumor antibiotics (mitomycin, bleomycin) [1,2].  Therefore, theoretical 
concerns exist regarding the use of antioxidant vitamins in combination with at least the above-mentioned 
standard tumor therapeutic agents. The fear is that antioxidant vitamins may protect normal and cancer cells 
against free radicals that are generated by chemotherapy and radiation therapy. Other agents, not known to 
generate free radicals, pose less concern. These include hormonal therapy, biological agents, antimetabolites, 
vinca alkaloids, and taxanes [3]. 
 
    Page 2 
            July 2006 
 
Historical position and rationale of practitioners of nutritional medicine. Practitioners of nutritional medicine 
have historically utilized antioxidant dietary supplements concomitant with chemotherapy and radiation.  In part 
the rationale for the use of antioxidants during chemotherapy is based on studies that suggest antioxidant levels 
are reduced in cancer patients during chemotherapy [4,5].  Additionally, albeit limited in number, all of clinical 
studies to date investigating the combination of chemotherapy/radiation therapy and antioxidants have 
demonstrated either beneficial effects or lack of interference. 
 
Chemotherapy and Antioxidants: Evidence Review 
 
Evidence supporting the concomitant use of antioxidants and chemotherapy  
 
In vitro studies: 
In a murine neuroblastoma model, administration of vitamin E enhanced antitumor activity of cisplatin 
in vivo [12].   In vitro studies with neuroblastoma, melanoma and non-small cell lung cancer cell lines 
have also shown that antioxidants can enhance the antitumor effects of 5-FU, cisplatin, doxorubicin and 
dacarbazine [13-15]. In vitro, vitamin C is reported to improve the antineoplastic activity of 
doxorubicin, cisplatin, and paclitaxil in human breast carcinoma cells [16]. 
 
The interactions between antioxidants and chemotherapy appear to be more complex than might be 
predicted solely on the basis of oxidative mechanisms.  Antioxidants have been shown to increase cell 
death by triggering apoptosis. A recent in vitro study demonstrated vitamin E induced apoptosis in 
colorectal cancer cells, and significantly enhanced tumor growth inhibition by 5-FU and doxorubicin 
[29].  This stimulation of apoptotic pathways may explain the synergistic effects of chemotherapy and 
radiation with antioxidant therapy. 
Animal studies: 
Despite the fact that chemotherapy-induced formation of free radicals is well demonstrated, both in vitro 
and animal studies have shown that the co-administration of antioxidants did not reduce the antitumor 
effect of cytostatic agents such as doxorubicicn and cisplatin.  Furthermore, the survival of animals co-
administered antioxidants was increased compared to the survival of animals that received 
chemotherapy alone [6-9]. 
 
Vitamin E pre-treatment did not interfere with the action of doxorubicin in rats with myeloid leukemia, 
but it did reduce cardiotoxicity [10].  A combination of vitamins A, C, and E, enhanced antitumor 
effects of doxorubicin on transplanted tumors in mice [11]. 
 
Clinical studies: 
In clinical studies, synthetic antioxidants did not alter the antitumor effect of chemotherapy [24-26]. In a 
randomized trial evaluating 100 breast cancer patients taking cyclophosphamide or doxorubicin, 
supplementation with vitamin A improved response rate to chemotherapy [27]. A combination of 
vitamins A (15,000 IU), C (2,000 mg.), E (300IU), beta-carotene (10,000IU), and selenium (800 mcg.) 
was co-administered with chemotherapy and radiation in an open trail of patients with small cell lung 
cancer. Two-year survival was greater than historical control [28]. A clinical trial in advanced non-small 
cell lung cancer randomized 70 patients to receive chemotherapy alone or chemotherapy plus the 
hormone antioxidant melatonin.  The response rate and one year survival was significantly greater in the 
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melatonin plus chemotherapy cohort [41].  Additionally myelosuppression, neurotoxicity, and cachexia 
were all reduced in the melatonin treated group. 
 
A good deal of evidence suggests that reactive oxygen species have an important role in certain 
chemotherapy-induced side effects. Examples include doxorubicin-induced cardiotoxicity, bleomycin-
induced pulmonary fibrosis, and cisplatin nephrotoxicity, ototoxicity and neurotoxicity. A recent review 
of the literature by Weijl et al. reports on numerous in vitro, animal and clinical studies (264 references) 
demonstrating a reduction in adverse effects from these chemotherapeutic agents with co-administration 
of various antioxidants [30]. Synthetic antioxidant cytoprotectants are routinely used by oncologists to 
attentuate the toxicity of chemotherapeutic agents and radiation therapy while preserving the 
effectiveness of such therapy. Examples include mesna for ifosfamide induced hemorrhagic cystitis, 
dexrazoxane for adriamycin cardiotoxicity and amifostine for cisplatin nephrotoxicity. These agents 
have been scrutinized through pre-clinical and clinical testing and found to be safe and efficacious [24-
26]. This further lends support to the argument that natural antioxidant supplementation could safely be 
combined with chemotherapy and radiation therapy. 
 
Evidence supporting the avoidance of antioxidants with chemotherapy 
In vitro studies: 
Other in vitro studies, however, have shown a reduction in antitumor effect when antioxidants ( N-
acetylcysteine, selenium, superoxide dismutase and catalase) and iron chelating agents were co-
administered with doxorubicin [17]. A similar in vitro effect was shown with vitamin A and doxorubicin 
[18].  Beta –carotene has been shown to reduce the effect of 5-FU in a murine fibrosarcoma model [19].  
Vitamin C enhanced doxorubicin resistance in human breast cancer cell lines [20]. Furthermore, it has 
been demonstrated that vitamin C reduced the cytotoxic effects of methotrexate and DTIC on 
neuroblastoma cell lines [40].   
 
Animal studies: 
N-acetylcysteine has been shown to reduce the effect of doxoxrubicin in one animal study and reduce 
the effect of cisplatin in vitro[21,22].  The bioflavinoid tangeretin, has been shown to inhibit the effect 
of tamoxifen on mammary cancer in a mouse model [23]. 
 
 
Radiation Therapy and Antioxidants: Evidence Review 
 
Evidence supporting the concomitant use of antioxidants and radiation therapy 
 
Animal studies: 
Ionizing radiation generates free radicals that damage DNA. Apoptosis may ensue as a result of 
radiation-induced cellular damage in normal and tumor cells. Limited studies are available in animals 
and humans, examining the effect of antioxidants administered during radiation therapy. Vitamin A and 
beta-carotene co-administered with local radiation, decreased tumor size and increased survival time in 
mice bearing human breast tumor cell lines, compared to treatment with radiation alone [31]. In mice, 
vitamin C has demonstrated a radio-sensitizing effect on tumors and a radio-protective effect on normal 
tissue [33 ]. The limited animal data on vitamin E suggest that typical therapeutic doses (<1,200 IU) 
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enhance the effect of radiation therapy while extremely high doses (35,000IU) may have the opposite 
effect [35].  
 
Clinical Studies: 
Vitamin A (cis-retinoic acid) and radiotherapy improved the tumor response rate in a clinical trial of 
locally advanced cervical cancer compared to historical controls [32]. A randomized human trial of 50 
patients evaluated the effect of combined Vitamin C 5gms/day and radiotherapy in different tumor types 
and noted more complete responses to radiation in the vitamin C group [34]. Radiotherapy co-
administered with melatonin 20 mg./day in 30 patients with glioblastoma demonstrated improved 
survival at one year compared to radiation therapy alone. Fewer radiation- induced side effects were 
observed in the melatonin treated group [36].  Patients randomized to receive intravenous glutathione 
(1200 mg.) administered just prior to adjuvant pelvic radiotherapy for endometrial cancer showed a 
significant reduction in radiation induced diarrhea compared to controls receiving radiation only [37]. 
 
Clinical Options Regarding Combining 
Antioxidants with Chemotherapy or Radiation Therapy 
 
 
We recognize that randomized controlled trials designed to determine the optimal dose and timing of 
antioxidants administered during chemotherapy and radiation are desirable. However it is also clear that patients 
are increasingly self-prescribing antioxidant therapy during chemotherapy and radiation therapy.  Several 
options are presented to help inform treatment decisions. The rationale for each is presented based on available 
evidence. 
 
Option A: Withhold any antioxidant therapy until all chemotherapy and radiation therapy is 
completed. As noted in the above discussion, only a limited number of clinical trials have been 
performed investigating the combination of chemotherapy/radiation therapy and antioxidants. Despite a 
suggestion of a beneficial effect from these studies, there have been no large randomized long-term 
clinical trials evaluating the effect of antioxidants administered concomitantly with chemotherapy or 
radiation therapy. The most conventional approach would therefore be to avoid antioxidant 
supplementation entirely until chemotherapy and radiation are completed. 
 
Option B: Avoid combining antioxidant therapy only with those chemotherapeutic agents known 
to induce formation of free radicals, and with radiation therapy. Alkylating agents, antitumor 
antibiotics, and topisomerase II inhibitors depend on the generation of free radicals for their therapeutic 
action. Ionizing radiation generates free radicals that damage DNA. Therefore, concurrent 
administration of antioxidants would theoretically, not be advisable for: 
 
Alkylating Agents: Busulfan, Carmustine, Lomustine, Chlorambucil, Cyclophosphamide, 
Cisplatin, Carboplatin, Ifosamide, Mechlorethamine, Melphalan, Thiotepa, Dacarbazine, 
Procarbazine 
Antitumor Antibiotics: Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Idarubicin, 
Mitomycin, Mitoxantrone, Plicamycin. 
Topoisomerase II inhibitor: Etoposide, Teniposide 
Radiation Therapy 
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On the other hand, certain chemotherapeutic agents are not known to rely on  oxidative mechanisms for 
their effect. Interference with the action of these agents by antioxidants is thus unlikely. These include 
hormonal therapy, biological agents, antimetabolites, vinca alkaloids, taxanes, and topoisomerase II 
inhibitors.  
 
Antimetabolites: Cytarabine, Fludarabine, Fluorouracil, Mercaptopurine, Methotrexate, 
 Thioguanine, Gemcitabine, Hydroxyurea 
Mitotic inhibitors:  Vincristine, Vinblastine, Vinorelbine 
Topoisomerase Inhibitors:  Topotecan, Irenotecan 
Miscellaneous:  Paclitaxel, Docetaxel, Asparaginase 
 
Option C: Antioxidant therapy might safely be considered if administered during a defined period 
of time so as not to interfere with the biologic activity of chemotherapy and radiation therapy. For 
chemotherapeutic agents which induce free radical production, the introduction of antioxidants could be 
timed so as to avoid a critical period defined by the pharmacodynamic properties of the 
chemotherapeutic agent involved. 
 
 
Pharmakodynamic Data for Chemotherapeutic Agents on the TJUH Formulary 
Drug Onset (days) Nadir (days) Recovery (days) 
Alkylating Agents 
Bulsufan 7-10 14-21 28 
Carboplatin NA* NA NA 
Carmustine 7-14 21-35 42-56 
Chlorambucil 7 14 28 
Cisplatin NA NA NA 
Cyclophosphamide 7 10-14 21 
Ifosfamide 7-14 21-28 21-28 
Lomustine 10-14 4-6 6-8 
Mechlorethamine 4-7 14 21 
Melphalan 7 8-32 42-50 
Thiotepa 7-10 14-30 NA 
Antibiotics 
Bleomycin 7 14 21 
Dactinomycin 7 14-21 21-28 
Daunarubicin 7 10-14 21-28 
Doxorubicin 7 10-14 21-28 
Liposomal Idarubicin 7 10-14 21-28 
Mitomycin 21 36 42-56 
Mitoxantrone 7-10 14 21 
Plicamycin 7-10 14 21 
Antimetabolites 
Cytarabine 4-7 14-18 21-28 
Floxuridine NA NA NA 
Fludarabine NA 8 5-7 wks 
Fluorouracil 7-10 14 21 
Mercaptopurine 7-10 14 21 
Methotrexate 7 10 21 
Thioguanine 7-10 14 21 
Mitotic Inhibitors 
Etoposide 10 7-14 21 
Vinblastine 4-7 4-10 17 
Vincristine 7 10 21 
Vinorelbine 4-7 7-10 14-21 
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Miscellaneous 
Aldesleukin NA NA  NA 
Azathioprine NA NA NA 
Cladribine NA NA NA 
Dacarbazine 7 21-25 21-28 
 *Data not available 
 
 
Option D: Allow the use of antioxidants concomitant with chemotherapy and radiation therapy. 
As documented in the preceding discussion, the overwhelming majority of available evidence to date 
suggests that neither natural or synthetic antioxidants reduce the toxicity of chemotherapy and radiation 
therapy without interfering with short term cytotoxic effects. However, most of the evidence cited above 
is either from in vitro or animal studies. Only a limited number of human trials of antioxidant 
supplementation have been completed in patients with breast and lung cancer [27,28,38,39]. These trials 
have demonstrated an increase in survival but are limited by their small sample sizes, limited duration, 
and comparisons based on historical controls. 
 
As to the documented safety of antioxidant supplementation with chemotherapy and radiation therapy, 
notable exceptions exist.  Until further data emerges, these exceptions can be used to alert clinicians and 
patients to potential adverse interactions between antioxidants and chemotherapy. Based solely on in 
vitro and animal studies cited above, the following precautions are recommended: 
• Avoid high doses of vitamin C with methotrexate and DTIC [40]. 
• Avoid vitamin A, vitamin C, selenium, and N-acetyl cysteine, with doxorubicin [17,18,20]. 
• Avoid beta carotene with 5-FU [19]. 
• Avoid N-acetylcysteine with cisplatin [21,22]. 
• Avoid citrus bioflavinoid supplements with tamoxifen [23]. 
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